FDA accepts Karyopharm's Xpovio combination application for myelofibrosis review

PUBT · 2d ago
FDA accepts Karyopharm's Xpovio combination application for myelofibrosis review
  • FDA accepted Karyopharm Therapeutics' supplemental application for XPOVIO in combination with ruxolitinib to treat myelofibrosis.
  • The agency set a June 28, 2027, target action date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611170730PR_NEWS_USPR_____NE99377) on November 17, 2026, and is solely responsible for the information contained therein.